CONSUN PHARMAC.GR.HD -10 - Asset Resilience Ratio
CONSUN PHARMAC.GR.HD -10 (C1P) has an Asset Resilience Ratio of 41.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CONSUN PHARMAC.GR.HD -10 leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how CONSUN PHARMAC.GR.HD -10's Asset Resilience Ratio has changed over time. See C1P net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down CONSUN PHARMAC.GR.HD -10's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of CONSUN PHARMAC.GR.HD -10.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.67 Billion | 41.64% |
| Total Liquid Assets | €2.67 Billion | 41.64% |
Asset Resilience Insights
- Very High Liquidity: CONSUN PHARMAC.GR.HD -10 maintains exceptional liquid asset reserves at 41.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CONSUN PHARMAC.GR.HD -10 Industry Peers by Asset Resilience Ratio
Compare CONSUN PHARMAC.GR.HD -10's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for CONSUN PHARMAC.GR.HD -10 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for CONSUN PHARMAC.GR.HD -10.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.64% | €2.67 Billion ≈ $3.12 Billion |
€6.41 Billion ≈ $7.49 Billion |
+25.27pp |
| 2024-12-31 | 16.37% | €958.00 Million ≈ $1.12 Billion |
€5.85 Billion ≈ $6.84 Billion |
+1.21pp |
| 2023-12-31 | 15.16% | €834.94 Million ≈ $976.13 Million |
€5.51 Billion ≈ $6.44 Billion |
+3.12pp |
| 2022-12-31 | 12.04% | €589.17 Million ≈ $688.80 Million |
€4.89 Billion ≈ $5.72 Billion |
+6.77pp |
| 2021-12-31 | 5.27% | €230.00 Million ≈ $268.89 Million |
€4.36 Billion ≈ $5.10 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more